Spravato
SPRAVATO™ (esketamine) is a nasal spray approved for use in conjunction with an oral antidepressant in adults with treatment-resistant depression (TRD).1
For more information regarding Spravato vs Ketamine, click here!
People who are currently struggling with major depressive disorder (MDD) may have TRD if they have not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode.2
SPRAVATO™ was approved by the U.S. Food & Drug Administration (FDA) on March 5, 2019, and is only available to patients at REMS–certified treatment centers in the United States.
Everything you need to know about Spravato